本帖最后由 老马 于 2012-1-13 21:20 编辑
8 E }& X* M! b+ y! ]% ~$ K. y4 D4 V+ P9 l' j" H& D
爱必妥和阿瓦斯丁的比较
4 T3 Z: \0 z) M9 @+ @
5 m9 ]; d: c1 v# @3 ^
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/ {3 [% @$ C9 o6 r0 m% F1 C
( g3 V. B7 Y3 i4 C" X. c& {2 x
B$ l* n w4 b0 G$ V5 k0 S
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
P: |) @% m# M7 s! m4 C. Z==================================================/ ?! c" f0 o/ N% t# a! y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 P7 c7 b4 t: S8 uPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.& A1 S# u% }1 G
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' V% F( L) B& O' u! a4 I/ r7 d
|